Orexigen Therapeutics, Inc. IPO Raises $84 Million, Middle of Range
Published: Apr 26, 2007
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on April 25, 2007. Any offer or sale will be made only by means of a written prospectus forming part of the effective registration statement. Copies of the final prospectus relating to the offering may be obtained from: Merrill Lynch & Co., 4 World Financial Center, New York, NY 10080.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state or jurisdiction.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, with an initial focus on obesity. Orexigen's lead combination product candidates targeted for obesity are Contrave(TM), which is in a Phase III clinical trial, and Empatic(TM) (formerly Excalia(TM)), which is in a Phase IIb clinical trial.
Contacts: Corporate Media Orexigen Therapeutics GendeLLindheim BioCom Partners Graham Cooper Stephen Gendel 858-436-8600 212-918-4650
CONTACT: Corporate: Graham Cooper for Orexigen Therapeutics,+1-858-436-8600; Media: Stephen Gendel of GendeLLindheim BioCom Partners,+1-212-918-4650
Ticker Symbol: (:OREX)